HistoSonics Announces First Treatment of BPH Patient With Vortx RX Device

HistoSonics announced the first use of its Vortx RX device to treat a patient with Benign Prostatic Hyperplasia in a pilot clinical trial at the University of Michigan's department of urology.


The Vortx RX is an investigational device and is based on histotripsy technology — a non-thermal focused ultrasound therapy that mechanically liquefies targeted tissues.

Urologist John Wei, MD, performed the first Vortx RX treatment at the university.

More Articles on Supply Chain:


Reducing Supply Chain Costs
First Navio Unicondylar Knee Replacement Performed in France
Abrams Royal Pharmacy Issues Voluntary Recall on All Unexpired Sterile Products

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers